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Pvaluation of the Accuracy of
adolinium-Enhanced Cardiovascular Magnetic
esonance in the Diagnosis of Cardiac Sarcoidosis
an-Peter Smedema, MD, MMED(INT), FCP(SA),*
abriel Snoep, MD,† Marinus P. G. van Kroonenburgh, MD, PHD,‡
obert-Jan van Geuns, MD, PHD,§ Willem R. M. Dassen, PHD,*
nton P. M. Gorgels, MD, PHD, FACC,* Harry J. G. M. Crijns, MD, PHD, FESC*
aastricht and Rotterdam, the Netherlands
OBJECTIVES This study analyzed the accuracy of gadolinium-enhanced cardiovascular magnetic resonance
(CMR) for the diagnosis of cardiac sarcoidosis (CS).
BACKGROUND The diagnosis of CS was made according to the guidelines of the Japanese Ministry of Health
and Welfare (1993); CMR has not been incorporated into the guidelines, and the diagnostic
accuracy of CMR for the diagnosis of CS has not yet been evaluated.
METHODS We performed an analysis of 12-lead electrocardiograms (ECGs), 24-h ambulatory ECGs,
echocardiograms, thallium scintigrams, and gadolinium-enhanced CMR studies in 58
biopsy-proven pulmonary sarcoidosis patients assessed for CS. The diagnostic accuracy of
CMR for CS was determined using modified Japanese guidelines as the gold standard.
RESULTS The diagnosis of CS was made in 12 of 58 patients (21%); CMR revealed late gadolinium
enhancement (LGE), mostly involving basal and lateral segments (73%), in 19 patients. In 8
of the 19 patients, scintigraphy was normal, while patchy LGE was present. The sensitivity
and specificity of CMR were 100% (95% confidence interval, 78% to 100%) and 78% (95%
confidence interval, 64% to 89%), and the positive and negative predictive values were 55%
and 100%, respectively, with an overall accuracy of 83%.
CONCLUSIONS In patients with sarcoidosis, CMR is a useful diagnostic tool to determine cardiac
involvement. New diagnostic guidelines should include CMR. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.0471683–90) © 2005 by the American College of Cardiology Foundation
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sarcoidosis is a multisystem granulomatous disorder of
nknown etiology with symptomatic cardiac involvement in
p to 7% of patients (1–3).
Postmortem studies reveal cardiac involvement in 20% to
0% of patients with sarcoidosis in the U.S. (4,5). In Japan,
ardiac involvement is present in as many as 58% of patients,
nd is responsible for as many as 85% of deaths from
arcoidosis (6,7). The clinical features of sarcoid heart
isease include congestive heart failure, cor pulmonale,
upraventricular and ventricular arrhythmias, conduction
isturbances, ventricular aneurysms, pericardial effusion,
nd sudden death (8). The diagnosis of cardiac sarcoidosis
CS) is made in the co-existence of non-caseating granulo-
as on myocardial biopsy and/or biopsies of any extracar-
iac tissue (with the exclusion of other causes of granulo-
atous inflammation such as mycobacterial or fungal
nfection) and cardiovascular abnormalities for which other
ossible causes have been excluded. The guideline from the
apanese Ministry of Health and Welfare provide an excel-
ent framework (9) (Table 1).
The guideline combines the results of various diagnostic
ests such as tissue biopsy, electrocardiography, echocardi-
graphy, and myocardial scintigraphy to either exclude or
From the Departments of *Cardiology, †Radiology, and ‡Nuclear Medicine,
niversity Hospital Maastricht, Maastricht, the Netherlands; and the §Departments
f Cardiology and Radiology, Erasmus Medical Centre, Rotterdam, the Netherlands.l
Manuscript received July 27, 2004; revised manuscript received January 13, 2005,
ccepted January 25, 2005.iagnose CS. Most diagnostic tests, including endomyocar-
ial biopsy, suffer of low sensitivity, low specificity, or both.
he most accurate diagnostic strategy for this condition is
urrently unknown. We aimed to assess the accuracy of
adolinium-enhanced cardiovascular magnetic resonance
CMR) in the diagnosis of CS with a modified guideline of
he Japanese Ministry of Health and Welfare (1993) as the
old standard.
Because of the limited diagnostic yield and invasive
ature of the procedure with an associated risk of morbidity,
e did not feel justified to systematically subject patients
ho were screened for CS to endomyocardial biopsy (10).
or the purpose of the present study, the Japanese guideline
as modified by excluding endomyocardial biopsy as a
iagnostic parameter (Table 1).
ETHODS
tudy population. Between July 1998 and May 2004, 58
atients with histologically proven pulmonary sarcoidosis
nderwent cardiac assessment in the cardiology departments
f Tygerberg Hospital (1 patient), Medical Centre Haag-
anden (1 patient), the Erasmus University Medical Centre
3 patients), and the University Hospital Maastricht (53
atients). The diagnosis of sarcoidosis was confirmed if the
linical presentation and chest radiographic finding were
upported by histological evidence of noncaseating granu-
omas by transbronchial biopsy, and if the possibility of
i
t
b
(
a
u
(
c
t
d
d
S
r
b
e
fi
W
i
E
r
s
e
k
[
b
v
a
t
t
b
m
c
s
E
5
i
s
R
w
m
T
e
2
S
S
h

c
u
a
w
d
(
C
r
a
c
E
t
c
e
h
a
p
m
t
m
g
a
1684 Smedema et al. JACC Vol. 45, No. 10, 2005
Diagnosing Cardiac Sarcoidosis With CMR May 17, 2005:1683–90nfection, environmental factors, or hypersensitivity reaction
o medication causing granulomatous inflammation had
een eliminated. The patients had either cardiac symptoms
16 patients) or were screened for cardiac involvement in the
bsence of cardiac symptoms (42 patients). All patients
nderwent clinical assessment, 12-lead electrocardiography
ECG), ambulatory ECG monitoring, transthoracic echo-
ardiography, 201thallium single-photon emission computed
omography (SPECT), and CMR. Patients underwent
iagnostic coronary angiography to exclude coronary artery
isease when a (partially) reversible perfusion defect on
PECT, decreased left ventricular ejection fraction, or
egional wall motion abnormalities were present.
Cardiac histology was obtained in five patients by cardiac
iopsy, and in three patients who had a postmortem
xamination. The diagnosis of CS, according to the modi-
ed guideline of the Japanese Ministry of Health and
elfare (Table 1), was made in 12 of 58 patients included
n the study.
CG and ambulatory ECG. A 12-lead surface ECG was
ecorded (MAC, Marquette, Milwaukee, Wisconsin; paper
peed 25 mm/s), and the findings were interpreted by two
xperienced cardiologists and classified as abnormal (i.e., in
eeping with the ECG criteria of the Japanese guideline
complete right bundle branch block or left bundle branch
lock, bifascicular block, third-degree atrioventricular block,
entricular tachycardia [VT], or pathological Q or ST-T
bnormalities]) or normal.
Ambulatory ECGs were performed for 24 to 72 h, and
hey were considered abnormal when intermittent atrioven-
ricular conduction delay or block, intermittent bundle
Abbreviations and Acronyms
CMR  cardiovascular magnetic resonance
CS  cardiac sarcoidosis
ECG  electrocardiography/electrocardiogram
LGE  late gadolinium enhancement
SPECT  single-photon emission computed tomography
VT  ventricular tachycardia
Table 1. Modified Guidelines for the Diagnosis
on Diffuse Pulmonary Diseases From the Japane
1. Histologic diagnosis group: endomyocardial biops
caseating granulomata.
2. Clinical diagnosis group: in patients with histolog
sarcoidosis is suspected when “a” and at least one
such as hypertension and coronary artery disease h
a. Complete RBBB, LBBB (included by the autho
pathological Q or ST-T change on resting or
b. Abnormal wall motion, regional wall thinning,
c. Perfusion defect by 201thallium-myocardial scin
99mTc-PYP myocardial scintigraphy.
d. Abnormal intracardiac pressure, low cardiac ou
fraction of the left ventricle. {the original guide
over moderate grade, even if the findings are nonAV  atrioventricular; LBBB  left bundle branch block; PVC 
branch block; VT  ventricular tachycardia.ranch blocks, or ventricular arrhythmias such as frequent
onomorphic and/or polymorphic premature ventricular
ontractions 100 per 24 h, nonsustained VTs, and/or
ustained VTs were found.
chocardiography. Studies were performed with a Sonos
500 phased-array imaging system (Hewlett Packard, Cal-
fornia) and considered abnormal when regional or global
ystolic dysfunction, wall thickening, or thinning was found.
egional differences in left ventricular wall enhancement
ere measured and localized according to the 17-segment
odel (11).
hallium myocardial scintigraphy. After treadmill peak
xercise, or during intravenous infusion of dipyridamol,
01thallium was administered and SPECT performed on a
iemens triple-detector gamma camera (MultiSPECT-3,
iemens, Erlangen, Germany), equipped with low-energy,
igh-resolution collimators. The images were made in a 64
64 matrix (60 frames/45 s). The thallium scan was
onsidered suggestive of CS when areas with reversed
ptake and/or irreversible perfusion defects were present
nd/or reversible perfusion defects were found in patients
ith normal coronary arteries at angiography. Regional
efects were localized according to the 17-segment model
11).
MR. Studies were performed using a 1.5-T magnetic
esonance imaging scanner (Philips, Best, the Netherlands,
nd General Electric, Milwaukee, Wisconsin) with a
ardiac-dedicated phased-array coil. The CMR studies were
CG-triggered by standard software and obtained in dias-
ole to minimize artifact due to cardiac motion. Studies
onsisted of steady-state-free precession in 58 patients, spin
cho in 57 patients, and fat-saturated T2-weighted breath
old sequences in 58 patients. Short-axis, vertical long-axis,
nd four-chamber views were obtained. Steady-state-free
recession sequences were performed to assess regional wall
otion abnormalities. T2-weighted studies were performed
o assess the presence of myocardial inflammation. Ten
inutes after the additional administration of 0.1 mmol/kg
adolinium-DTPA (Schering, Berlin, Germany), short-axis
nd four-chamber images were obtained with spin echo in
ardiac Sarcoidosis Based on the Study Report
inistry of Health and Welfare, 1993 (9)
onstrates epithelioid granulomata without
gnosis of extracardiac sarcoidosis, cardiac
iteria “b” to “d” is present, and other etiologies
een excluded:
ft-axis deviation, AV block, VT, PVC, or
atory electrocardiogram.
ilation of the left ventricle.
hy or abnormal accumulation by 67Ga-citrate or
or abnormal wall motion or depressed ejection
entioned: e. Interstitial fibrosis or cellular infiltration
fic}of C
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May 17, 2005:1683–90 Diagnosing Cardiac Sarcoidosis With CMR7 patients (slice thickness 8 mm, gap 0.8 mm, matrix 512
512, field of vision 380 mm, voxel size 0.7 mm 0.7 mm
8 mm) and three-dimensional breath hold inversion
ecovery-gradient echo sequences (short-axis, vertical long-
xis, four-chamber) in 16 patients (slice thickness 10 mm,
o gap, matrix 256 256, field of vision 400 mm, voxel size
.6 mm  1.6 mm  10 mm) to assess for the presence of
adolinium-enhancing lesions (LGE). Fifteen patients had
oth spin echo and inversion recovery-gradient echo studies.
he inversion time (250 to 400 ms) was determined on an
Table 2. Summary of Demographic and Backg
G
Cardi
Mean age (yrs)
Functional class
No complaints
Modified NYHA (class 0–IV) 0
I
II
III
IV
Time (yrs) since diagnosis of sarcoidosis
Pulmonary stage (I–IV) 1
Steroid treatment
Hypertension
Palpitations
Syncope
ACE maximal (IU/l)
Abnormal ECG
Abnormal ambulatory ECG
Abnormal echocardiogram
Abnormal thallium scintigram
CMR
Regional contrast enhancement
Number of enhancing segments 3
Decreased LVEF
Mean LVEF (%)
Loss of wall thickness
ACE  angiotensin converting enzyme; CMR  cardiovasc
ventricular ejection fraction; NYHA  New York Heart As
able 3. Twelve Patients With Cardiac Sarcoidosis (Modified Jap
Patient
#
Age
(yrs) Gender
Time Since
Diagnosis
of
Sarcoidosis
(yrs) Symptoms Thallium
1 53 M 10 Heart failure
2 50 F 4 Palpitations
3 52 F 30 Heart failure Normal
4 55 F 7 Heart failure Abnorma
5 41 M 1 Palpitations Abnorma
6 42 M 5 Palpitations Normal
7 43 M 14 Heart failure
8 43 M 6 Palpitations Normal
9 54 M 15 Heart failure Normal
10 54 M 5 Heart failure Normal
11 41 M 10 None Abnorma
12 52 M 4 SyncopeV  atrioventricular; bifasc  bifascicular; CMR  cardiovascular magnetic resonance;
ranch block; nsVT  nonsustained ventricular tachycardia; RBBB  right bundle branchndividual basis to obtain optimal nulling of the unenhanced
yocardial signal.
Regional differences in left ventricular wall enhancement
ere measured and localized according to the 17-segment
odel (11) (MASS suite post-processing software, MEDIS,
eiden, the Netherlands). The total time required for the
nvestigation was 30 to 45 min.
The studies were independently evaluated by four blinded
bservers, three cardiologists, and one radiologist with
xperience in contrast-enhanced CMR. The studies were
d Medical Data
With
rcoidosis
12)
Group Without
Cardiac Sarcoidosis
(n  46) p Value
6 47  10 NS
0.01
%) 40 (87%)
1.6 0.2  0.5
1
3
0
0
8 6  9 NS
1 2.2  1.2 NS
%) 31 (67%) NS
10 (23%) 0.05
%) 13 (30%) NS
) 2 (5%) NS
40 30  17 NS
0%) 3 (7%) 0.0001
%) 6 (13%) 0.01
%) 3 (7%) 0.01
%) 5 (11%) NS
%) 8 (17%) 0.0001
3.6 0.5  1.3 0.0001
%) 3 (7%) 0.0001
15 59  5 0.0001
%) 1 (2%) NS
agnetic resonance; ECG  electrocardiogram; LVEF  left
on.
e Guideline)
chocardiography CMR ECG Holter EMB
1 1,2 ST-T 0 Noncaseating
granuloma
1 1 ST-T VT
1 1,2 Pseudoinfarct nsVT Fibrosis
1 1,2 LBBB 0
1 1,3 ST-T nsVT Fibrosis
0 1 Bifasc block 0
1 2 LBBB nsVT Fibrosis
0 1 RBBB 0
1 1,2 3rd AV block 0
0 1,2 3rd AV block 0
1 1 ST-T 0
1 1,2,3 Pseudoinfarct nsVTroun
roup
ac Sa
(n 
49 
9 (69
.9 
0
2
0
2
9 
.8 
12 (92
0
4 (31
1 (8%
35 
13 (10
7 (58
6 (46
3 (43
12 (92
.3 
7 (54
48 
2 (15anes
E
l
l
lECG  electrocardiogram; EMB  endomyocardial biopsy; LBBB  left bundle
block; VT  ventricular tachycardia.
Table 4. Abnormal Findings With CMR
Patient #
Age
(yrs) Gender CMR Segments Diagnosis ECG Holter Echocardiography Thallium Segments
1 53 M LGE: 1,3,4,6,8,9,10,11,12,15, all layers,
some confluent transmural lesions;
regional wall motion abnormalities;
LVEF 50% (Fig. 2)
CS (guideline) ST-T 0 LVEF 50%
2 50 F LGE: 2,3,6, all layers CS (guideline) ST-T VT Hyperecoïcity
3 52 F LGE: 1,2,3,5,6,7,8,9,13,14,15,16, all
layers, some confluent transmural
lesions; regional wall motion
abnormalities; LVEF 30% (Fig. 3)
CS (guideline) pseudoinfarct nsVT LVEF 30%
4 55 F LGE: 1,6, involving all layers; LVEF 51% CS (guideline) LBBB 0 LVEF 30% Reversed uptake, 1,6,7,12
5 41 M LGE: 11,16,17, all layers, some confluent
transmural lesions; loss of wall
thickness, regional wall motion
abnormalities
CS (guideline) ST-T nsVT HCM Partly reversible, 13,14,16,17
6 42 M LGE: 7, mid-myocardial layer CS (guideline) Bifasc block PVCs 0 0
7 43 M LVEF 20% CS (guideline) LBBB nsVT LVEF 20%
8 43 M LGE: 2,3, involving all layers CS (guideline) RBBB 0 0 0
9 54 M LGE: 1,2,3,4,7,8,9,10, all layers; regional
wall motion abnormalities; LVEF 35%
(Fig. 4)
CS (guideline) 3rd AV block 0 dilated RV  LV,
LVEF 46%
0
10 54 M LGE: 2,6, involving all layers; LVEF 56% CS (guidelines) 3rd AV block 0 0 0
11 41 M LGE: 5,12, all layers CS (guideline) ST-T Mild MVP Irreversible, 10,15
12 52 M LGE: 5,6,11,12, all layers, some confluent
transmural lesions; loss of wall
thickness, regional wall motion
abnormalities; LVEF 40% (Fig. 5)
CS (guidelines) Pseudoinfarct nsVT Hypokinesia,
4,5,10,11,15,16
LVEF 40%
13 47 M LGE: 7, mid-myocardial layer Undetermined 0 0 0 0
14 39 M LGE: 2, sub-endocardial layer Undetermined 0 0 0 Irreversible, 10,15
15 49 F LGE: 1,2,9,11,12, all layers Undetermined 0 0 0 Reversed uptake, 1,2,7,8
16 48 M LGE: 3,4,5,6,9,10, all layers Undetermined 0 0 0 0
17 44 F LGE: 1,5, sub-endocardial layer (Fig. 6) Undetermined 0 0 0 0
18 67 F LGE: 2,4, sub-endocardial layer Undetermined 0 0 0 0
19 50 M LGE: 13,14,15,17, sub-endocardial and
transmural, loss of wall thickness,
LVEF 20%
CAD LBBB 0 Apical dyskinesia,
LVEF 34%
Irreversible, 1,6,7,12
20 58 M LGE: 2,3, sub-endocardial layer CAD 0 0 0 Reversible inferior
21 39 M LVEF 50% Aortic valve
regurgitation
0 0 LVEF 50% 0
22 69 F LVEF 30% DCM RVH 0 LVEF 30% 0
bifasc bifascicular; CAD coronary artery disease; CS cardiac sarcoidosis; DCM dilated cardiomyopathy; HCM hypertrophic cardiomyopathy; LGE late gadolinium enhancement; LV left ventricle; LVEF left ventricular
ejection fraction; MVP  mitral valve prolapse; PVC  premature ventricular contractions; RV  right ventricle; RVH  right ventricular hypertrophy; other abbreviations as in Table 3.
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May 17, 2005:1683–90 Diagnosing Cardiac Sarcoidosis With CMRonsidered to be abnormal when at least two independent
bservers described identical abnormalities.
tatistical analysis. All statistical analyses were performed
sing the statistical software package SSPS version 11.5
SPSS Inc., Chicago, Illinois). Group data are expressed as
ean values  SD. Continuous variables were assessed
sing the parametric t test for independent samples or
ann-Whitney test where appropriate, and all categorical
ariables were assessed using the chi-square test. Statistical
ignificance was defined as a p value 0.05.
ESULTS
atient characteristics. A total of 58 patients were as-
essed. Twelve of the patients were diagnosed with CS
ccording to the modified guidelines. The demographic,
linical, and diagnostic findings for the groups with CS and
ithout CS are shown in Tables 2 and 3. The ages, gender,
ace, the time between cardiac evaluation and the diagnosis
f sarcoidosis, and pulmonary stage did not differ signifi-
antly between the groups. Functional class was significantly
oorer in the patient group with CS compared to the group
ithout CS due to heart failure.
MR. Table 4 summarizes the findings of the CMR
tudies. In 40 (69%) studies 4 out of 4 observers, in 13 (22%)
tudies 3 out of 4 observers, and in 5 (9%) studies 2 out of
observers agreed on the absence or the presence and
ocalization of LGE. Late gadolinium-enhancing lesions
ere present in 19 patients (mean 3.6 segments per patient,
ange 1 to 12 segments). Nine of 19 patients had evaluation
ith spin echo, 9 patients with spin echo and inversion
ecovery-gradient echo, and 1 patient had only inversion
ecovery-gradient echo. In 5 of the spin echo patients, two
bservers, and in 3 of the spin echo patients 3 observers
greed on the presence and localization of LGE, whereas in
of the 10 patients who had both spin echo and inversion
ecovery-gradient echo or only inversion recovery-gradient
cho all observers agreed on the presence and localization of
GE.
Most enhancing lesions were located in the basal and
ateral left ventricular segments (segments 1 to 7, 11, 12, 16;
0 of 71 enhancing segments [73%]) (Fig. 1). In 10 patients,
igure 1. Bull’s eye plots demonstrating left ventricular segmentation (left)
reference 11) and the distribution of late enhancement per segment in 19
arcoidosis patients (right).significantly reduced left ventricular systolic function (left
a
hentricular ejection fraction 20% to 51%, mean 36%) was
eported, 7(54%) with CS, 1 patient with dilated cardiomy-
pathy, 1with valvular heart disease, and 1 with coronary
rtery disease (Figs. 2A, 2B, 3, and 4). In three patients,
egional loss of wall thickness was found, two patients with
S (Figs. 5A and 5B), and one with coronary artery disease.
welve of the 22 patients with abnormal CMR studies were
iagnosed with CS according to the modified guideline.
verall, the diagnosis of CS according to the modified
uideline was made in 12 of 58 sarcoidosis patients (21%).
The sensitivity and specificity of contrast-enhanced
MR was 100% (one-sided 95% confidence interval, 78%
o 100%) and 78% (95% confidence interval, 64% to 89%),
nd the positive and negative predictive values were 55%
igure 2. (A) Cardiovascular magnetic resonance study (inversion
ecovery-gradient echo, short-axis view, 10 min after administration of 0.1
mol/gadolinium-DTPA) of patient 1, a 53-year-old man with a history
f stage 2 pulmonary sarcoidosis, who presented with congestive cardiac
ailure. Arrows point toward the enhanced myocardial segments (10, 11,
nd 12). (B) The end-systolic frame (steady-state-free precession, short-
xis view) of this slice demonstrated regional loss of wall thickness and
ypokinesia of the gadolinium-enhanced segments (10, 11, and 12).
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Diagnosing Cardiac Sarcoidosis With CMR May 17, 2005:1683–90nd 100%, respectively, with an overall accuracy of 83%.
ardiovascular magnetic resonance showed one to six
ontrast-enhancing myocardial lesions in six patients who
ad not been diagnosed with CS according to the modified
uideline.
In eight patients, CMR (five with spin echo, three with
pin echo and inversion recovery-gradient echo) diagnosed
GE, although 201thallium scintigraphy was normal. In six
f the eight patients, LGE involved only one or two
egments, whereas in two patients, six and eight segments,
espectively, were involved. In three patients, LGE involved
ne myocardial layer, sub-endocardial or midmyocardial; in
ne patient both subendocardial and midmyocardial layers
ere involved, and in four patients patchy involvement of all
hree myocardial layers was present (Fig. 6), without con-
uent transmural involvement.
ISCUSSION
he prognosis of sarcoidosis is mainly determined by
ulmonary and cardiac involvement (12,13). Multivariate
nalysis identified New York Heart Association functional
lass, left ventricular end-diastolic diameter, and the pres-
nce of sustained VTs as independent predictors of mortal-
ty (14).
It is important to accurately diagnose cardiac involve-
ent. The guideline published by the Japanese Ministry of
ealth and Welfare (1993) provides us with an excellent
ramework for diagnosis, but the techniques utilized lack
ensitivity and specificity in the absence of a diagnostic
ndomyocardial biopsy.
Magnetic resonance imaging is a robust imaging tech-
ique that enables us to evaluate cardiac structure, function,
nd tissue characteristics with high-image resolution. It may
igure 3. Cardiovascular magnetic resonance study (inversion recovery-
radient echo, short-axis view, 10 min after administration of 0.1 mmol/
adolinium-DTPA) of patient 4 demonstrated extensive late gadolinium
nhancement, involving 33% of the left ventricle.uide the cardiologist when taking endomyocardial biopsies
a
end increase the sensitivity of this technique (15,16). Serial
MR studies are possible because of the absence of expo-
ure to ionizing radiation, and they may evaluate disease
ctivity and extent in response to therapy.
Postmortem studies in sarcoid patients have revealed the
resence of varying amounts of myocardial scar tissue,
hich is considered to be the substrate for lethal ventricular
rrhythmias (4,5,12–14). Gadolinium-DTPA (Gd-DTPA)
s an extracellular CMR contrast agent. Histological assess-
ent of Gd-DTPA–enhanced myocardium has been cor-
elated with local fibrosis and active myocarditis (16–18).
agner et al. (19) have demonstrated the superior ability of
adolinium-enhanced CMR to diagnose even small
mounts of myocardial scar tissue in patients with coronary
rtery disease when compared with myocardial scintigraphy.
Several case reports and small single-center patient series
ave demonstrated the diagnostic potential of CMR in CS
20–28). So far no study has systematically evaluated the
iagnostic accuracy of CMR for the presence of CS using
he diagnostic Japanese guideline as the gold standard. The
urrent study is part of a prospective initiative that aims to
valuate the prevalence of cardiac involvement in patients
ith sarcoidosis and determine the most accurate and
ost-effective diagnostic strategy for CS.
The diagnostic accuracy of CMR compares well to the
echniques employed in the diagnostic framework of the
apanese guideline.
The fact that the combination of ECG and CMR saves
aluable time at equal cost compared with our previously
mployed diagnostic pathway of ECG, echocardiography,
nd SPECT (cost in the Netherlands, respectively, €222
nd €205) makes it an attractive alternative.
The low positive predictive value of 55% reflects the
igure 4. Cardiovascular magnetic resonance study (inversion recovery-
radient echo, four-chamber view, 10 min after administration of 0.1
mol/gadolinium-DTPA) of patient 10, a 54-year-old man with a history
f stage 3 pulmonary sarcoidosis, who was referred with grade III
trioventricular block. Arrows point toward the gadolinium-DTPA–
nhanced myocardial segments (2 and 8).
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May 17, 2005:1683–90 Diagnosing Cardiac Sarcoidosis With CMRuperior spatial resolution of CMR; CMR is able to detect
mall myocardial lesions that have not resulted in conduc-
ion delay, re-polarization abnormalities, or regional
hanges in wall thickness or function, and, hence, are not
etected by ECG, echocardiography, or SPECT.
Unfortunately, even small myocardial scars may result in
rrhythmias, and the follow-up of this patient population
ill determine the significance of our findings. For this
eason, CMR may become very important for the early
etection of cardiac involvement and for identifying pulmo-
ary sarcoidosis in patients at risk of sudden death.
Most of the enhancing lesions (73%) were localized in the
igure 5. (A) Cardiovascular magnetic resonance study (three-dimensional
reath-hold inversion recovery-gradient echo, short-axis view, 10 min after
dministration of 0.1 mmol/gadolinium-DTPA) of patient 12 demon-
trated loss of wall thickness and late gadolinium enhancement (segments
1 and 12). This patient survived out-of-hospital cardiac arrest secondary
o ventricular fibrillation. (B) Cardiovascular magnetic resonance study
steady-state-free precession, four-chamber view) of patient 12 demon-
trated loss of wall thickness and late gadolinium enhancement (segments
1 and 12).asal and lateral left ventricular wall. These findings corre-
1
aate with the findings at postmortem assessment of sarcoid-
sis patients, where most lesions were found in the men-
ioned segments (4,5).
Although in some patients LGE was transmural, result-
ng in loss of wall thickness and regional wall motion
bnormalities, lesions in most patients were patchy, affect-
ng several myocardial layers. The presence of patchy LGE
as also been reported in patients with dilated cardiomyop-
thy, but our findings clearly differ from the distribution of
GE in patients with coronary artery disease (29).
Considering the diagnostic limitations of electrocardiog-
aphy, 25% of patients with extensive cardiac involvement in
he study by Roberts et al. (5) had normal ECGs, and
ecause of the superior spatial resolution of CMR compared
ith scintigraphy, new diagnostic guidelines need to be
ompiled that include CMR.
onclusions. In patients with sarcoidosis, CMR is a useful
nd cost-effective diagnostic tool to determine cardiac in-
olvement. The combination of ECG with CMR was as
ccurate but more time- and cost-effective compared with
CG, ambulatory ECG, echocardiography, and SPECT
or the diagnosis of CS. Cardiovascular magnetic resonance
iagnosed small myocardial lesions, not diagnosed by ECG,
chocardiography, or SPECT, that might be of prognostic
elevance.
tudy limitations. Ideally, CMR findings should correlate
ith CMR-guided endomyocardial biopsy (i.e., myocardial
istology). In our study, CMR findings were compared with
linical guidelines. In only four patients, myocardial histol-
gy was obtained.
In only 16 of 58 (28%) patients was the inversion
ecovery-gradient echo studies performed. Because inver-
ion recovery-gradient echo increases contrast between un-
nhanced and gadolinium-enhanced myocardium up to
igure 6. Cardiovascular magnetic resonance study (spin echo, short-axis
iew) of patient 17 demonstrated late gadolinium enhancement (segmentsand 4) in a patient in whom standard assessment had not revealed
bnormalities.
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issue (30). Although we used only spin echo sequences to
ssess for the presence of late enhancement in 42 patients,
nd might have underestimated the presence and extent of
adolinium enhancement in some patients, we were still
ble to detect enhancement in nine (21%) of these patients.
ecommendations for further study. There is a need for
ulticenter studies that will determine the diagnostic accu-
acy of CMR and studies into the prognostic implications of
ontrast-enhanced CM-detected CS not detected by con-
entional methods. Early treatment may possibly prevent
udden death and deterioration of ventricular function and
esult in improved prognosis.
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